ACE inhibition is emerging as a valuable adjunct to other drugs used after acute myocardial infarction (MI). This therapy has been validated in a number of major trials (see Table I), although questions remain regarding the optimal approach.
|Number of pages||5|
|Publication status||Published - Oct 1996|
ASJC Scopus subject areas